Videos
Defining the Optimal Immunotherapy Strategy in Resectable Non-Small Cell Lung Cancer
03/14/2026
At Great Debates Solid Tumors in Miami, Florida, Kelsey Pan, MD, from Emory University in Atlanta, Georgia, discusses whether a neoadjuvant-only immunotherapy approach may be sufficient for patients with resectable non-small cell lung cancer.
Drawing on data from trials such as CheckMate 816, Dr Pan compares neoadjuvant-only and perioperative strategies—both of which show comparable improvements in event-free survival—and emphasizes the need for biomarkers to guide decisions about additional adjuvant therapy.
Source:
Pan K. Resectable lung cancer: Neoadjuvant only vs perioperative therapy. Presented at Great Debates - Solid Tumors; Miami, Florida. March 14-15, 2026.
